ELAVL2 Antibody

What is ELAVL2 and what are its main biological functions?

ELAVL2 is an RNA-binding protein that contains three conserved RNA recognition motifs (RRM1-3). Its biological functions include:

• Acting as a tumor suppressor in glioblastoma (GBM), where it inhibits mesenchymal transition

• Stabilizing mRNAs of epithelial-to-mesenchymal transition (EMT) inhibitory molecules like SH3GL3 and DNM3

• Playing an essential role in the formation of primordial follicles in mouse ovaries

• Regulating the translation of proteins involved in P-body assembly, particularly DDX6

• Controlling mRNA stability through direct association with target transcripts

Understanding these functions is crucial for designing experiments with ELAVL2 antibodies that properly address the biological context being studied.

What epitopes do most commercial ELAVL2 antibodies target?

Most ELAVL2 antibodies target either:

• N-terminal regions (amino acids 1-100)

• C-terminal regions (amino acids 300-359)

• Specific RNA recognition motifs (RRMs)

When selecting an antibody, it's important to consider whether the epitope might interfere with protein-protein or protein-RNA interactions being studied. For RNA-binding studies, antibodies targeting regions outside the RRM domains may be preferable to avoid disrupting RNA-protein interactions .

How can I validate the specificity of my ELAVL2 antibody?

Proper validation should include:

• Testing on ELAVL2 knockout tissues/cells as negative controls (as demonstrated in the research where ELAVL2 immunostaining confirmed absence of expression in knockout ovaries)

• Western blot analysis to confirm the expected molecular weight (approximately 39-42 kDa)

• Testing for cross-reactivity with other ELAVL family members (ELAVL1/HuR, ELAVL3, ELAVL4), which share sequence homology

• Peptide competition assays to confirm specificity for the target epitope

• Multiple antibody approach using antibodies raised against different epitopes to confirm results

What are the optimal conditions for using ELAVL2 antibodies in immunohistochemistry/immunofluorescence?

Based on published research methodologies:

• Fixation: 4% paraformaldehyde is most common

• Antigen retrieval: Citrate buffer (pH 6.0) for paraffin sections

• Blocking: 5-10% normal serum (from secondary antibody species)

• Primary antibody dilution: Typically 1:100-1:500, optimized for each antibody

• Incubation: Overnight at 4°C for best results

• Signal detection: Fluorescent-conjugated secondaries for co-localization studies

• Controls: Include ELAVL2 knockout tissues when available

For co-localization studies, ELAVL2 has been successfully co-stained with c-KIT as an oocyte marker and with P-body components such as DDX6, DCP1A, and AGO2 .

How should I optimize RNA immunoprecipitation protocols using ELAVL2 antibodies?

The following protocol has been validated in published research:

• Sample preparation:

  • Homogenize tissues in IP buffer (20 mM HEPES/KOH, pH 7.5, 150 mM NaCl, 2.5 mM MgCl₂, 0.1% NP-40, 1 mM DTT, protease inhibitors, and RNase inhibitor)

  • Clear lysate by centrifugation (10,000 × g at 4°C for 10 min)

• Immunoprecipitation:

  • Pre-incubate magnetic protein G beads with anti-ELAVL2 antibody (5 μg has been effective)

  • Incubate lysate with antibody-bead complex for 6 hours at 4°C with gentle rotation

  • Perform stringent washes (3-5 times) with IP buffer

• RNA extraction and analysis:

  • Elute RNA-protein complexes with buffer containing 0.5% SDS at 70°C

  • Extract RNA using TRIzol reagent

  • Proceed with RT-qPCR or RNA-seq analysis

This approach has successfully identified 2,519 genes as putative ELAVL2-associating mRNAs using stringent criteria (IP/input > 2) .

What are the critical parameters for Western blot detection of ELAVL2?

For optimal Western blot results:

• Sample preparation: Complete protease inhibitor cocktail is essential to prevent degradation

• Protein loading: 30-50 μg total protein per lane typically provides sufficient signal

• Gel percentage: 10-12% SDS-PAGE provides good resolution for the 39-42 kDa ELAVL2 protein

• Transfer: Semi-dry or wet transfer to PVDF membrane (nitrocellulose also works)

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: 1:1000-1:2000 dilution, overnight at 4°C

• Detection: Enhanced chemiluminescence with appropriate exposure time

When analyzing ELAVL2 knockout samples, researchers have confirmed complete absence of the protein band, validating both knockout models and antibody specificity .

How can ELAVL2 antibodies be used to investigate its role in glioblastoma?

ELAVL2 has been identified as a critical tumor suppressor in glioblastoma . Research applications include:

• Expression profiling:

  • Immunohistochemistry of patient samples to correlate ELAVL2 expression with clinical outcomes

  • Tissue microarray analysis has demonstrated that high ELAVL2 protein expression confers favorable survival outcomes in GBM patients

• Mechanistic studies:

  • RIP-seq to identify ELAVL2-bound transcripts in GBM cells

  • Immunoprecipitation followed by mass spectrometry to identify protein interactors

  • Assessment of mRNA stability of EMT-inhibitory molecules in the presence/absence of ELAVL2

• Therapeutic development:

  • Screening assays to identify compounds that modulate ELAVL2 expression or activity

  • Monitoring ELAVL2 levels following treatment with experimental therapeutics

Research has shown that ELAVL2 directly binds to and stabilizes transcripts of EMT-inhibitory molecules, potentially through an m6A-dependent mechanism .

What methodologies can be used to study ELAVL2's role in RNA granule formation?

ELAVL2 plays a critical role in P-body-like granule assembly in oocytes . Key methodologies include:

• Quantitative imaging approaches:

  • Measurement of DDX6 foci per unit area (1 μm²) of oocytes

  • P-body component co-localization analysis with ELAVL2

  • Time-course imaging during development

• Functional assessment:

  • Comparison between wild-type and ELAVL2 knockout tissues

  • Expression analysis of P-body components at mRNA and protein levels

  • Western blot quantification of key components like DDX6, which shows decreased expression (34% of wild-type levels) in ELAVL2 knockout ovaries

• Structure-function analysis:

  • Transfection of wild-type vs. RRM-mutant ELAVL2 constructs

  • Assessment of RNA binding using reporter constructs with target 3'-UTRs

  • Rescue experiments in ELAVL2-deficient models

Research has demonstrated that deletion of RRM1 and RRM2 domains reduces RNA binding to approximately one-tenth of wild-type levels .

How can I determine if ELAVL2 directly regulates a specific mRNA target?

To validate direct regulation:

• RIP-qPCR approach:

  • Immunoprecipitate ELAVL2-RNA complexes using validated antibodies

  • Quantify enrichment of candidate target mRNAs by RT-qPCR

  • Compare to control immunoprecipitations (IgG or in ELAVL2-depleted cells)

• Reporter assays:

  • Clone the 3'-UTR of candidate targets into reporter constructs

  • Co-transfect with ELAVL2 expression vectors

  • Assess reporter expression/stability in the presence/absence of ELAVL2

  • Test with wild-type vs. RRM-mutant ELAVL2 to confirm RNA-binding dependency

• Functional validation:

  • Assess target mRNA and protein levels in ELAVL2 knockout/knockdown models

  • Measure mRNA stability (actinomycin D chase) with/without ELAVL2

  • Perform rescue experiments by reintroducing ELAVL2

Researchers have demonstrated direct binding of ELAVL2 to DDX6 mRNA via its 3'-UTR, where interaction was greatly increased in a sequence-dependent manner and diminished when using RRM-mutant ELAVL2 .

Why might I observe discrepancies between ELAVL2 mRNA and protein levels?

Several factors may contribute to such discrepancies:

• Post-transcriptional regulation:

  • ELAVL2 itself is an RNA-binding protein that may be subject to auto-regulation

  • Other RNA-binding proteins may regulate ELAVL2 mRNA stability or translation

  • miRNAs targeting ELAVL2 mRNA

• Technical considerations:

  • Antibody specificity issues (cross-reactivity with other ELAVL family members)

  • Differences in assay sensitivity between RNA and protein detection methods

  • Protein degradation during sample preparation

• Biological factors:

  • Tissue-specific translational control mechanisms

  • Developmental stage-dependent regulation

  • Disease-specific alterations in post-transcriptional mechanisms

Research suggests that ELAVL2 may play multiple roles in a context- or developmental stage-dependent manner .

What are common pitfalls when analyzing ELAVL2 knockout or knockdown experiments?

When working with ELAVL2-deficient models:

• Incomplete knockout/knockdown:

  • Verify knockout at both DNA (genotyping) and protein levels (Western blot)

  • Check for compensatory upregulation of other ELAVL family members

  • Assess potential residual expression of splice variants or truncated proteins

• Secondary effects:

  • Distinguish between direct ELAVL2 targets and indirect downstream effects

  • Consider time-dependent changes following ELAVL2 loss

  • Account for potential developmental defects in constitutive knockout models

• Tissue-specific phenotypes:

  • ELAVL2 knockout mice show severe ovarian defects while testes exhibit no clear morphological abnormalities

  • Progressive death of knockout mice (>80% by weaning) may complicate analysis of adult phenotypes

How can I quantitatively assess changes in ELAVL2-regulated RNA granules?

Based on published methodologies:

• Quantitative image analysis:

  • Measure area of RNA granule foci per unit area of cells/tissues

  • Count number of granules per cell

  • Assess granule size distribution

• Biochemical approaches:

  • Subcellular fractionation followed by Western blot analysis of granule components

  • Density gradient centrifugation to isolate and characterize RNA granules

  • Cross-linking followed by immunoprecipitation to identify granule-associated RNAs

• Comparison metrics:

  • Researchers have quantified DDX6 foci in ELAVL2 knockout ovaries, finding approximately 75% reduction compared to wild-type tissues

  • Western blot analysis showed DDX6 protein expression decreased to 34% of wild-type levels in ELAVL2 knockout ovaries

How might ELAVL2 antibodies contribute to understanding m6A-dependent RNA regulation?

Recent findings suggest ELAVL2 may function through m6A-dependent mechanisms:

• Investigation approaches:

  • RIP-seq with ELAVL2 antibodies followed by m6A-seq of bound transcripts

  • Comparative analysis of m6A patterns in wild-type vs. ELAVL2-deficient tissues

  • Competition assays to determine if m6A enhances or inhibits ELAVL2 binding

• Functional studies:

  • Analysis of m6A reader/writer/eraser interactions with ELAVL2

  • Assessment of how m6A modification affects ELAVL2-mediated transcript stability

  • Examination of co-localization between ELAVL2 and m6A machinery components

Research has indicated that ELAVL2 may stabilize EMT-inhibitory molecules through an m6A-dependent mechanism in glioblastoma .

What is known about the differential roles of ELAVL2 in various tissue contexts?

ELAVL2 exhibits context-dependent functions:

• Neural tissues:

  • Originally identified in relation to neural development

  • May regulate neuronal transcript stability and translation

• Reproductive tissues:

  • Essential for primordial follicle formation in ovaries

  • Regulates P-body assembly and translation of DDX6

  • No reported major defects in male reproductive tissues despite expression

• Cancer contexts:

  • Functions as a tumor suppressor in glioblastoma

  • Inhibits mesenchymal transition by stabilizing EMT-inhibitory transcripts

  • Most frequently deleted in GBM compared to other cancers

This tissue-specific functionality should be considered when designing experiments and interpreting results with ELAVL2 antibodies.

How can ELAVL2 antibodies be used in multiplexed imaging approaches?

Advanced multiplexed imaging with ELAVL2 antibodies:

• Multi-color immunofluorescence:

  • Co-staining with cell-type markers (e.g., c-KIT for oocytes)

  • Simultaneous detection of multiple RNA granule components (DDX6, DCP1A, AGO2)

  • Assessment of co-localization with RNA markers (FISH combined with immunofluorescence)

• Technical considerations:

  • Select antibodies raised in different species to avoid cross-reactivity

  • Optimize antibody dilutions to achieve balanced signal intensities

  • Consider sequential staining protocols for antibodies from the same species

• Analysis approaches:

  • Quantitative co-localization metrics (Pearson's correlation, Mander's overlap)

  • 3D reconstruction to analyze spatial relationships of granules

  • Time-lapse imaging to study dynamic assembly/disassembly of granules